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Abstract
Background: T cell development results in the generation of both mature ab and cd T cells. While ab T cells predominate in
secondary lymphoid organs, cd T cells are more abundant in mucosal tissues. PU.1, an Ets family transcription factor, also
identified as the spleen focus forming virus proviral integration site-1 (Sfpi1) is essential for early stages of T cell
development, but is down regulated during the DN T-cell stage.
Methodology/Principal Findings: In this study, we show that in mice specifically lacking PU.1 in T cells using an lck-Cre
transgene with a conditional Sfpi1 allele (Sfpi1
lck2/2) there are increased numbers of cd T cells in spleen, thymus and in the
intestine when compared to wild-type mice. The increase in cd T cell numbers in PU.1-deficient mice is consistent in cd T cell
subsets identified by TCR variable regions. PU.1-deficient cd T cells demonstrate greater proliferation in vivo and in vitro.
Conclusions/Significance: The increase of cd T cell numbers in Lck-Cre deleter strains, where deletion occurs after PU.1
expression is diminished, as well as the observation that PU.1-deficient cd T cells have greater proliferative responses than
wild type cells, suggests that PU.1 effects are not developmental but rather at the level of homeostasis. Thus, our data
shows that PU.1 has a negative influence on cd T cell expansion.
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Introduction
T cells are divided into two populations based on their surface
expression of ab and cd T cell receptors (TCR). cd Tc e l l sf u n c t i o ni n
immunosurveillance playing a significant role in innate immunity,
autoimmunity and allergic responses [1]. cd T cells constitute only a
small proportion (1–5%) of the lymphocytes that circulate in the
blood and peripheral organs of most adult animals however; they are
morewidelydistributed within epidermaland mucosal tissues, suchas
the skin, intestine and reproductive tract comprising up to 50% of T
cells. Both ab and cd T cells arise from common multipotent DN
precursors in the thymus that can be further separated into four DN
subsets based on CD44 and CD25 expression [2,3]. Commitment to
the T cell lineage is complete at the DN3 stage where the cells
undergo extensive DNA rearrangements at the b, c and d TCR loci
in order to express functional TCR chains and make a choice
between two developmental programs, one generating ab Tc e l l
subsetsand onegenerating the distinct characteristics and functions of
cd T cells [4,5].
The molecular events involved in cd lineage commitment are
poorly understood. Numerous signals impact on the cd Tc e l ll i n e a g e
including, TCR signal strength, notch signaling, IL-7R signaling and
the presence of DP thymocytes [6–10]. Expression of the
transcription factor Sox13 promotes cd Tc e l ld e v e l o p m e n tw h i l e
opposing ab T cell differentiation. Mice deficient in Sox13 exhibit
impaired cd T cell development but not ab Tc e l l s[ 1 1 ] .T h e
expression of c-Jun is not required for, and may antagonize, cd Tc e l l
development [12]. The role of other transcription factors in
regulating cd Tc e l ld e v e l o p m e n ta n dp e r i p h e r a lh o m e o s t a s i sh a s
not been examined.
PU.1 is an Ets family transcription factor that is essential for
lymphoid and myeloid development [13]. PU.1 mRNA is expressed
in hematopoietic stem cellsand in the earliest thymic precursors but is
downregulated during the pro-T cell stage. Decreased expression of
PU.1 is necessary for continued progress through T cell differenti-
ation [14]. Our lab has previously shown that ab T cell development
is normal in mice that conditionally lack PU.1 in T cells [15].
HowevertheexpressionofPU.1inTcellsandsubpopulationsofTh2
cells contributes to heterogeneity in Th2 cytokine expression and
TCR expression [16]. In this report we have shown that deletion of
PU.1resultsinincreasednumbersofcdT cells in various organs. Our
results suggest that PU.1 has negative influence on cd Tc e l l
expansion in the periphery.
Results
cd T cell numbers are expanded in the absence of PU.1
Previous work demonstrated that PU.1 functions in T cells by
contributing to heterogeneity of TCR expression and Th2
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development of ab T cells was not affected in the absence of PU.1
[15–17]. In the characterization of mice that conditionally lack
PU.1 following Lck-Cre mediated deletion of Sfpi1, we examined
the effects of PU.1-deficiency on other T cell subsets. Flow
cytometry of splenocytes and thymocytes showed similar profiles of
CD3+ abTCR and CD3+ NKT cells between wild-type and
Sfpi1
lck2/2 mice (Fig. 1A). This is consistent with progressively
diminished expression of Sfpi1 throughout the stages of DN T cell
development in the thymus (Fig. 1B). However, Sfpi1 is expressed
in peripheral CD4+ naı ¨ve ab T cells (Fig. 1C). We examined other
T cell subsets and observed that splenic cd T cells had greater Sfpi1
expression than ab T cells (Fig. 1C). Sfpi1 expression was lower in
cd T cells isolated from thymus, or intraepithelial lymphocytes,
and was undetectable in cd T cells isolated from skin (Fig. 1C).
These results are consistent with a previous report that detected
PU.1 expression in cd T cells derived from fetal thymic organ
culture [18].
Thus we next examined cd T cell in mice that lack expression of
PU.1 in T cells. To determine if Lck-Cre deleted in cd T cells,
genomic DNA was isolated from purified cd T cells from spleen
and thymus and tested for deletion of the Sfpi1 allele. Although
deletion was not complete as previously observed in double-
positive thymocytes [15], there was at least 50% deletion in cd T
cell populations (Fig. 2A). In contrast to the absence of an effect of
PU.1 deletion on ab T cells, we observed a consistent increase in
the numbers of cd T cells in a number of organs and tissues. Using
flow cytometry to examine the percentages of cells positive for
CD3 and cd TCR, we observed significantly increased percent-
ages of cd T cells in spleen, thymus and among intra-epithelial
lymphocytes (IEL) in the intestine, though not in the skin (Fig. 2B
and data not shown). Since PU.1-deficiency does not significantly
Figure 1. T cell development is normal in Sfpi1
lck2/2 mice. (A) Flow cytometric analysis of cells in spleen and thymus from Sfpi1
lck2/2 mice and
wild-type control mice. The CD3+ abTCR+ and CD3+ NK1.1+ T cell percentages are presented as mean 6 SEM of six mice. Percentages were not
significantly different between WT and Sfpi1
lck2/2 mice (p.0.05). (B) Thymocytes from wild-type control mice were sorted into double-negative
subpopulations and RNA was analyzed for Sfpi1 expression. (C) The indicated T cell populations were sorted and RNA was analyzed for Sfpi1
expression by qPCR. Results are averages 6 SEM of values from three mice. ND, not detected.
doi:10.1371/journal.pone.0022189.g001
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percentages of cd T cells corresponds to increased numbers of cd
T cells in these organs (Fig. 2B). We further examined the
expression of other surface proteins on wild type and PU.1-
deficient splenic cd T cells. Greater than 90% of the cells were
CD5-positive regardless of PU.1 expression, and the increase in cd
T cells in the absence of PU.1 occurred similarly in CD24-positive
and CD24-negative populations (data not shown). There were
some differences in the expansion of cd T cell subsets that
expressed CD62L and/or CD44, and though all populations
demonstrated a trend towards increased numbers in the absence of
PU.1, only the CD62Lhi, CD44hi population was significantly
increased (Fig. 2C).
Sfpi1
lck2/2 mice contain enhanced numbers of cd T cell
subsets
To determine if these expanded populations included all subsets
of cd T cells identified by specific Vc and Vd TCRs, we examined
the populations of cells that were positive for CD3 and Vc2o r
Vd4. We observed significantly increased percentages of Vc2+ and
Vd4+ T cells in all organs examined (Fig. 3). Concomitant with the
increase in percentages, there was an increase in cell numbers of
each of these cd T cell subsets (Fig. 3).
The absence of PU.1 results in enhanced cd T cells
proliferation
We next examined whether PU.1-deficiency affected cd T cell
function or gene expression. The expansion of cd T cells in the
absence of PU.1 suggested that cell proliferation might be affected.
To assess this in vivo we injected mice with BrdU to determine the
percentage of cd T cells in cell cycle. We observed a significant
increase in the percentage of BrdU-positive PU.1-deficient cd T
cells, compared to wild type cells (Fig. 4A). To define proliferation
in vitro, thymic cells were labeled with the fluorescent dye CFSE
and activated with plate bound anti-CD3 and anti-CD28 for 72 h.
Cell division was analyzed by flow cytometry. cd T cells from
Sfpi1
lck2/2 mice had greater proliferation than cells from wild-type
mice, determined by staining profile, mean fluorescence intensity
of CFSE staining, and proliferative index (Fig. 4B–C). In contrast,
PU.1 had only modest effects on apoptosis (Fig. 4D). Using qPCR
we tested the expression of transcription factors previously shown
to affect cd T cell development, including Gata3, Sox13 and Jun
[11,12,19]. We did not observe any significant differences in the
expression of these transcription factors in cd T cells from wild-
type and Sfpi1
lck2/2 mice (Fig. 4E). Previous reports have
demonstrated that cd T cells can secrete IFNc and IL-17 in
response to TCR stimulation [20–22] and the cytokine secretion
pattern may vary with antigen exposure [23]. To test the cytokine
production from PU.1-deficient cd T cells, we purified cd T cells
from wild-type and Sfpi1
lck2/2 splenocytes using flow cytometry
and stimulated them with anti-CD3. After 72 hours, supernatants
were collected and tested for amounts of IFNc and IL-17 using
ELISA. Amounts of IFNc produced were similar between wild-
type and PU.1-deficient cd T cells, consistent with similar
expression of Tbx21 and with similar percentages of cd T cells
that were CD122-positive (Fig. 4F and data not shown). There was
a trend towards more IL-17 production from PU.1-deficient cd T
cells than from wild type cells, though this was not statistically
significant (Fig. 4G). Although there was no difference in the
expression of Rorc between in wild-type and PU.1-deficient cd T
cells, we did observe a significant increase in the numbers of cd T
cells that were CCR6+, supporting a selective increase in the
populations of some cytokine secreting cd T cells in the absence of
PU.1 (Fig. 4H and data not shown).
Discussion
The development of cd T cells is still not completely
understood. Development is regulated by extracellular signals
and the expression of cell-intrinsic factors that regulate develop-
ment and expansion. In this report we identify PU.1 as a
transcription factor that regulates numbers of cd T cells in
secondary lymphoid organs and at mucosal sites. This represents a
distinct function of PU.1 between ab and cd T cells, since ab T
cell development and numbers in various lymphoid organs is
unaltered by PU.1-deficiency. Thus, this study has identified a
novel function of PU.1 and contributes further to our under-
standing of transcription factor control of cd T cell homeostasis.
PU.1 is expressed in cd T cells from several organs. Splenic cd
T cells have higher expression of Sfpi1 than naı ¨ve CD4+ T cells,
although Sfpi1 is expressed in lower amounts by thymic and
intraepithelial intestinal cd T cells, and not expressed in dermal cd
T cells. Since dermal cd T cells have a fetal thymic origin [1], it is
possible that there may be a difference in PU.1 expression between
cd T cells that derive during embryonic development and mature
mice. PU.1 expression was observed in cd T cells derived from
fetal thymic organ culture suggesting that a fetal thymus does not
result in the absence of PU.1 expression in cd T cells [18]. Further
studies will be required to determine precisely when Sfpi1 is
regulated during cd T cell development.
The point at which PU.1-deficiency affects cd T cell
homeostasis is difficult to define. Although cd T cell commitment
during DN T cell development may occur at several stages [24]
deletion by Lck-Cre, which occurs after Sfpi1 expression is
diminished between DN1 and DN2 and extinguished by DN3,
is unlikely to affect cd T cell development. In support of this idea,
we did not see alterations in the expression of transcription factors
that mediate ab/cd T cell lineage decisions. Moreover, it is likely
that the phenotype observed is cell-intrinsic, and not due to the
reported effects of ab T cells on cd T cell development [10]
because deletion of Sfpi1 by CD4-Cre, where Sfpi1 is deleted in all
ab T cells did not effect cd T cell numbers in spleen or thymus
(data not shown). We did observe that proliferation of thymic cd T
cells was increased in vivo and in vitro in the absence of PU.1.
However, this does not distinguish between proliferation of cd T
cells during or after development, and it is still possible that PU.1
functions at both stages. The precise functions PU.1 regulates will
require a greater understanding of cd T cell homeostasis.
We demonstrate that PU.1-deficiency increases in vivo prolifer-
ation of cd T cells, and in vitro TCR-induced proliferation of cd T
cells. In several cell types PU.1 can function as a tumor suppressor
Figure 2. Increased cd T cells in Sfpi1
lck2/2 mice. (A) cd TCR+ thymocytes and cdTCR+ splenocytes were sorted from wild-type and Sfpi1
lck2/2
mice and genomic DNA was analyzed for the presence of the wild-type (WT; +), floxed (fl), or deleted (D) allele. (B) Flow cytometric analysis of cd T
cells in spleen, thymus and intestine (intra-epithelial lymphocytes) from wild-type and Sfpi1
lck2/2 mice using antibodies specific for CD3 and pan-cd
TCR. Numbers in dot plots represent the mean 6 SEM of 10–12 mice. The absolute number of cd T cells was calculated by multiplying the total cell
number recovered from each organ by the percentage of cd T cells. Results are an average of 10–12 mice. (C) Flow cytometric analysis of cd T cells in
spleen from wild-type and Sfpi1
lck2/2 mice using antibodies specific for pan-cd TCR, CD62L and CD44. Numbers are cd T cells in each subpopulation
and are averages 6 SEM of three mice. *Significantly different from WT, p,0.05 determined by Student’s t test.
doi:10.1371/journal.pone.0022189.g002
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decreased expression of PU.1 is dependent on Jun [27]. Thus while
Jun is not required for cd T cell development [12], and we did not
observe differences in the expression of Jun, it is possible that in the
absence of PU.1, Jun may help to promote expansion of T cells. In
various cell types PU.1 has also been shown to induce expression of
TRAIL and Ink4b, which respectively induce apoptosis and inhibit
cell proliferation [28,29]. It may ultimately be a combination of
effects on multiple genes that allows PU.1 to regulate cd T cell
expansion.
In the initial descriptions of PU.1, it was thought to be largely
restricted to myeloid lineages [30]. During T cell development
PU.1 expression is decreased between DN1 and DN2, and is
extinguished by DN3. However, PU.1 is expressed in naı ¨ve CD4+
T cells, and we have shown that it regulates the expression of TCR
in T cells, decreasing the threshold of activation [15]. We have
also demonstrated that PU.1 limits the expression of Th2 cytokines
and contributes to Th2 heterogeneity [15,16]. Importantly, PU.1
promotes the development of Th9 cells [17]. In contrast to these
effects, we did not observe significant effects of PU.1-deficiency on
Figure 3. cd T cell subsets in Sfpi1
lck2/2 mice. Flow cytometric analysis of cd T cells in the indicated organs using antibodies specific for CD3 and
individual Vc or Vd TCR regions. Numbers in dot plots represent the mean 6 SEM of 4 mice and are representative of three independent experiments.
The absolute number of individual cd T cell subsets was calculated by multiplying the total cell number recovered from each organ by the
percentage of cd T cells. *, Significantly different from WT, p,0.05 determined by Student’s t test.
doi:10.1371/journal.pone.0022189.g003
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lck2/2 cd T cells. (A) Wild-type and Sfpi1
lck2/2 mice were injected
with BrdU and after 24 hours thymocytes were stained with antibodies to cd TCR and BrdU. Results are average 6 SEM. (B–C) Splenocytes were
stained with CFSE and stimulated with anti-CD3 and anti-CD28, and analyzed for the CFSE staining on cd T cells after 72 hours. CFSE staining profiles
are shown (B). The mean fluorescence intensity of CFSE and the proliferation index of the populations are presented as the mean 6 SEM of three
mice. (D) cd T cells from spleen of wild-type and Sfpi1
lck2/2 mice were stained with PE-Annexin V and percentages of annexin V positive cells are
indicated. (E) RNA was isolated from sorted cd T cells from spleen and thymus of wild-type and Sfpi1
lck2/2 mice before analysis of mRNA using qPCR.
Results are the average 6 SEM of 5–6 mice. (F-G) cd T cells were purified from spleen by flow cytometry and stimulated with anti-CD3 for 3 days
before IFN-c and IL-17 concentrations in supernatants were quantified using ELISA. Data are representative of two independent experiments and
represent mean 6 SEM of replicate samples. (H) cd T cells in spleen from wild-type and Sfpi1
lck2/2 mice were stained using antibody specific for
CCR6. Numbers are cd T cells in each subpopulation and are averages 6 SEM of three mice. *, Significantly different from the WT, p,0.05 determined
by Student’s t test.
doi:10.1371/journal.pone.0022189.g004
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distinct effects in various types of T cells, negatively regulating cd
T cell numbers, negatively regulating Th2 cytokine production
and TCR expression, while promoting IL-9 expression [15–17].
In this report we describe the effects of PU.1-deficiency on the
cd T cell population. The transcription factor network that
promotes the development and homeostasis of cd T cells is not
well-defined. Our demonstration that deletion of PU.1 results in
expansion of cd T cells, an effect that is restricted to this subset,
adds to our understanding of the regulation of cd T cells. Further
work will help to define how this factor limits cd T cell expansion.
Materials and Methods
Ethics Statement
Mice were maintained in pathogen-free conditions and all
studies were approved by the Indiana University School of
Medicine Animal Care and Use committee.
Mice
Wild-type C57BL/6 female mice were purchased from Harlan
Bioscience. Mice with conditional deletion of the PU.1 gene
(Sfpi1
lck2/2) on the C57BL/6 background were previously described
[31] and mated to mice carrying a Cre transgene under control of an
Lck promoter (B6(CBA)-Tg(Lck-cre)I540Jxm/J). The examination of
allele deletion was performed as previously described [31]. Mice were
used at age 6–8 weeks.
Cell Isolation and Flow cytometry
Splenocytes and thymocytes of both wild-type and Sfpi1
lck2/2
were harvested and single cell suspensions were obtained. Viable
cells were counted and determined by trypan blue exclusion. IELs
were isolated by incubation of cleaned intenstine followed by Ficoll
gradient centrifugation as described previously [32]. Splenocytes,
thymocytes and IELs were then preincubated with Fc-block
(2.4G2, BD pharmingenTM) for 10 minutes, followed by
incubation with anti-CD3 PE, anti-cdTCR FITC, anti-Vc2dTCR
FITC, anti-Vd4TCR FITC or antibodies to other surface proteins
for 30 minutes at 4uC. Stained cells were analyzed with the BD
FACSCalibur flow cytometer. All antibodies were purchased from
BD Pharmingen unless otherwise stated.
Cell proliferation and apoptosis assay
For BrdU studies, mice were administered 2 mg of BrdU intra
peritoneally24 hpriortoanalysis.Todetectincorporation ofBrdU,
cells were stained with mAb specific to BrdU using a FITC-BrdU
flow kit (BD Biosciences) following manufacturer’s instructions.
For CFSE labeling, cd T cells were isolated from both wild-type
and Sfpi1
lck2/2 by staining splenocytes and thymocytes with PE
anti-cdTCR before sorting with FACSAria (Becton Dickinson).
Sorted cd T cells from spleen of wild-type and Sfpi1
lck2/2 mice
were washed in PBS, resuspended at a concentration of 10
6 cells/
ml and incubated with 5 mM of CFSE (Invitrogen) at 37uC for 10
minutes. Cells were then washed with cold culture media
supplemented with 10% FBS. CFSE labeled cells were cultured
for 3 days in anti-CD3 coated plates and soluble anti-CD28 (anti-
CD3 4 mg/ml). The cell division status of cells was determined by
measuring CFSE fluorescence after 3 days. Apoptosis was
measured by annexin V staining according to the manufacturer’s
protocol (BD Pharmingen). Briefly, cd T cells were washed with
PBS supplemented with 10% FBS and then resuspended at a
concentration of 10
6 cells/ml in binding buffer. Cells were then
stained with PE-Annexin V and incubated for 15 minutes. After
incubation cells were resuspended in 400 ml of binding buffer and
analyzed by flow cytometry within 1 h.
Cytokine secretion assays
The purified cd T cells were stimulated in vitro at 1610
6 cells/
well in duplicate with 2 mg/mL plate-coated anti-CD3 antibody
(BD Biosciences, San Jose, CA) for 72 hours. Supernatants were
collected and assayed for the presence of cytokines IFN-c and IL-
17 by ELISA.
Genomic DNA extraction and polymerase chain reaction
analysis
The DNA was extracted from cd T cells sorted from spleen or
thymus using DNeasy Blood and Tissue kit from Qiagen. PCR was
performed using primer/probe sets as described previously [31].
RNAwasextractedfrom sorted cdT cellsfromtheindicatedorgans
using Trizol. Quantitative real-time polymerase chain reaction was
performed using Taqman Fast Universal PCR Master Mix and the
plate was run on a 7500 Fast Real-Time PCR system (Applied
Biosystems, Foster City, CA). RNA was normalized to expression
levels of b2-microglobulin and relative expression was calculated
using the -DDCt method.
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